TY - ABST
T1 - Plasma galectin-9 is associated with clinical disease activity in treatment naïve early rheumatoid arthritis, unaffected by D-mard treatment, and in vitro modulates the secretion of MCP-1 and IL-6 in rheumatoid arthritis synovial fibroblasts
AU - Nielsen, Morten Aagaard
AU - Køster, Ditte
AU - Stengaard-Petersen, K
AU - Busson, Pierre
AU - Hørslev-Petersen, K
AU - Hetland, Merete Lund
AU - Østergaard, Mikkel
AU - Hvid, M
AU - Kragstrup, Tue W
N1 - COPECARE
PY - 2022
Y1 - 2022
N2 - Background: Fibroblast-like synoviocytes (FLS) are pivotal mediators of rheumatoid synovitis expansive growth and invasiveness which respond insufficiently to disease-modifying antirheumatic drugs. Galectin-9 (Gal-9) is a lectin with well-conserved carbohydrate-recognition domains. Gal-9 has been reported to have both pro- and anti-inflammatory properties based on its ability to modulate RA FLS. Gal-9 levels are elevated in serum of rheumatoid arthritis (RA) patients, and high levels of Gal-9 have been identified in both the synovial fluid and in the inflamed synovial tissue of patients with RA.
AB - Background: Fibroblast-like synoviocytes (FLS) are pivotal mediators of rheumatoid synovitis expansive growth and invasiveness which respond insufficiently to disease-modifying antirheumatic drugs. Galectin-9 (Gal-9) is a lectin with well-conserved carbohydrate-recognition domains. Gal-9 has been reported to have both pro- and anti-inflammatory properties based on its ability to modulate RA FLS. Gal-9 levels are elevated in serum of rheumatoid arthritis (RA) patients, and high levels of Gal-9 have been identified in both the synovial fluid and in the inflamed synovial tissue of patients with RA.
M3 - Conference abstract for conference
SP - Annals of the Rheumatic Diseases 81 Suppl 1: 462
T2 - EULAR 2022
Y2 - 1 June 2022 through 4 June 2022
ER -